ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 98 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $621,000 | -12.4% | 84,047 | +72.2% | 0.01% | 0.0% |
| Q3 2018 | $709,000 | -28.1% | 48,798 | -1.2% | 0.01% | -36.4% |
| Q2 2018 | $986,000 | +34.1% | 49,392 | +17.8% | 0.01% | +37.5% |
| Q1 2018 | $735,000 | -35.6% | 41,946 | -9.4% | 0.01% | -33.3% |
| Q4 2017 | $1,141,000 | -11.2% | 46,289 | -7.0% | 0.01% | -14.3% |
| Q3 2017 | $1,285,000 | -6.9% | 49,783 | -2.1% | 0.01% | -12.5% |
| Q2 2017 | $1,380,000 | -13.0% | 50,869 | -4.3% | 0.02% | -11.1% |
| Q1 2017 | $1,586,000 | +51.0% | 53,170 | +37.5% | 0.02% | +38.5% |
| Q4 2016 | $1,050,000 | – | 38,677 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |